Under the Radar Nano Cap Silexion is One to Watch as KRAS-Targeting Heats Up

TL;DR: FDA Breakthrough for Revolution Medicine’s Daraxonrasib and Verastem’s Progress Further Highlight the Excitement Surrounding the KRAS-targeting landscape; Silexion Positioned as an Under-the-Radar Player in the Field as it Advances Unique RNAi Approach

Silexion Therapeutics (NASDAQ: SLXN) appears to be approaching a pivotal inflection point as the biotechnology company advances its innovative RNA interference (RNAi) platform targeting KRAS-driven cancers. Recent competitive developments in the sector underscore the intense industry focus on KRAS-targeted therapies, while Silexion’s unique approach positions it distinctively in this rapidly evolving landscape.

The Market Landscape for KRAS Targetted Therapies

The KRAS-targeting field has seen significant validation in recent months. In June 2025, daraxonrasib (Revolution Medicines) received FDA breakthrough therapy designation for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) with KRAS G12 mutations. The designation, based on promising Phase 1 trial results, expedites development of Revolution’s Phase 3 RASolute 302 trial, which is expected to complete enrollment this year with readout anticipated in 2026.

Similarly, Verastem Oncology announced in June 2025 that it dosed the first patient with VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in a U.S. Phase 1/2a trial. The competitive focus on KRAS G12D is particularly relevant, as this mutation represents 26% of all KRAS mutations, making it the most prevalent variant in human cancers, occurring most commonly in pancreatic (37%), colorectal (12.5%), and non-small cell lung (5%) cancers.

Notably, no therapies are currently approved by the FDA specifically targeting KRAS G12D mutations, despite more than 90% of PDAC patients having tumors driven by RAS mutations, with approximately 85% harboring KRAS G12 mutations.

Silexion’s Differentiated RNAi Approach

While competitors focus on small-molecule inhibitors targeting specific KRAS mutations, Silexion’s RNAi platform offers broader applicability. The company’s next-generation candidate, SIL-204, demonstrated in preclinical studies that it can inhibit multiple KRAS mutations, including G12D, G12V, G12R, Q61H, and G13D.

In March 2025, Silexion reported breakthrough results from orthotopic pancreatic cancer models showing systemically administered SIL-204 achieved approximately 70-80% reduction in tumor cell numbers across multiple cancer cell lines. Most significantly, the studies demonstrated for the first time that SIL-204 “significantly reduced metastatic spread to secondary organs; substantially lowering metastatic burden across the liver, intestine, spleen and stomach.”

Strategic Expansion Beyond Pancreatic Cancer

Building on its LODER™ foundation, which achieved a 56% objective response rate in Phase 2 pancreatic cancer trials, Silexion completed comprehensive preclinical studies in May 2025 evaluating SIL-204, its next generation candidate, across multiple cancer types. The studies assessed GP2D (colorectal cancer), A427 (lung cancer), and Panc-1 (pancreatic cancer) cell lines, representing combined global treatment markets “worth well over US $30 billion a year,” according to the company.

Silexion has established strategic partnerships to support clinical advancement. The April 2025 collaboration with Catalent focuses on optimizing both systemic and intratumoral delivery formulations at Catalent’s Limoges, France facility. Earlier work with Evonik Corporation demonstrated that “a single systemic administration of SIL-204 maintained effective drug levels in rat plasma and tissues for over 56 days.”

The company’s March 2025 expanded development plan features a “dual-route strategy” integrating intratumoral and systemic administration to target both primary tumors and metastases. Silexion has outlined regulatory submissions to the Israel Ministry of Health in H2 2025 and to the European Union in H1 2026, with the goal of “initiating human trials in H1 2026.”

Positioned for Multiple Catalysts

With competitive validation emerging across the KRAS-targeting landscape and Silexion’s unique RNAi approach demonstrating promising multi-cancer preclinical results, the company appears positioned for a series of value-driving catalysts. The convergence of clinical validation, strategic partnerships, expanded market opportunity, and clear development timelines suggests Silexion may be approaching its breakthrough moment in the increasingly competitive KRAS-targeted cancer treatment space.